JMP Securities reissued their market outperform rating on shares of DBV Technologies (NASDAQ:DBVT – Free Report) in a report released on Tuesday morning, Benzinga reports. They currently have a $5.00 target price on the stock.
Other equities research analysts have also recently issued reports about the company. HC Wainwright restated a buy rating and set a $5.00 target price on shares of DBV Technologies in a research note on Thursday, August 1st. StockNews.com initiated coverage on DBV Technologies in a research report on Thursday, September 19th. They set a hold rating for the company.
Check Out Our Latest Stock Report on DBV Technologies
DBV Technologies Stock Performance
DBV Technologies (NASDAQ:DBVT – Get Free Report) last released its earnings results on Tuesday, July 30th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.08). DBV Technologies had a negative net margin of 638.21% and a negative return on equity of 74.41%. The firm had revenue of $1.16 million during the quarter, compared to the consensus estimate of $1.42 million. During the same period in the prior year, the business earned ($0.26) earnings per share. On average, research analysts predict that DBV Technologies will post -1.43 earnings per share for the current fiscal year.
Institutional Trading of DBV Technologies
An institutional investor recently raised its position in DBV Technologies stock. Yiheng Capital Management L.P. lifted its position in shares of DBV Technologies S.A. (NASDAQ:DBVT – Free Report) by 6.2% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,568,909 shares of the company’s stock after acquiring an additional 327,345 shares during the quarter. DBV Technologies makes up approximately 0.2% of Yiheng Capital Management L.P.’s portfolio, making the stock its 15th biggest position. Yiheng Capital Management L.P. owned 2.89% of DBV Technologies worth $4,172,000 at the end of the most recent reporting period. 71.74% of the stock is currently owned by institutional investors.
About DBV Technologies
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.
Featured Stories
- Five stocks we like better than DBV Technologies
- What is Short Interest? How to Use It
- Rocket Lab Stock Soars: Should Investors Chase the Rally?
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- KB Home Slips After Earnings: What’s Next for Homebuilders?
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Micron Stock Soars as AI Demand Fuels Big Q4 Earnings Beat
Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.